Description: Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Home Page: www.inozyme.com
INZY Technical Analysis
321 Summer Street
Boston,
MA
02210
United States
Phone:
857 330 4340
Officers
| Name | Title |
|---|---|
| Mr. Axel Bolte M.B.A., M.Sc. | Co-Founder, Pres, CEO & Director |
| Mr. Henric Bjorn Bjarke | Sr. VP & COO |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer |
| Mr. Sanjay S. Subramanian M.B.A., M.S. | CFO & Principal Accounting Officer |
| Dr. Soojin Kim Ph.D. | Sr. VP & Chief Technical Operations Officer |
| Dr. Yves Sabbagh Ph.D. | Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer |
| Mr. Stefan Riley | Director of Investor Relations |
| Ms. Gayle Gironda | Sr. VP & Chief People Officer |
| Dr. David Thompson M.A., M.S., Ph.D. | Chief Devel. Officer |
| Mr. Stephen J. Di Palma M.B.A, M.B.A. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3806 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-07-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 50 |